StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Nexium (esomeprazole) — Europe product sales by Year

Nexium (esomeprazole) — Europe product sales ($M) ($M)

AstraZeneca Nexium (esomeprazole) — Europe product sales: $50M in FY2025, down 16.7% from a year earlier.

Latest, FY2025
50
Period ended Dec 31, 2025
Change on a year earlier
-16.7%
60 in FY2024
History
6 years
Since FY2020
Sources
6
Documents cited below

Where the FY2025 figure comes from

“|| Nexium | 816 | (6) | (5) | 67 | (30) | 611 | 3 | 5 | 50 | (18) | (20) | 88 | (26) | (26)”

Source: Form 6-K FY2025Q4 Earnings Release ↗

Reported in Form 6-K / 20-F Product Sales Table.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNexium (esomeprazole) — Europe product sales ($M) ($M)Year on yearSource
FY2025Dec 31, 202550-16.7%Form 6-K FY2025Q4 Earnings Release ↗
FY2024Dec 31, 202460+13.2%Form 6-K FY2024Q4 Earnings Release ↗
FY2023Dec 31, 202353+15.2%Form 6-K FY2023Q4 Earnings Release ↗
FY2022Dec 31, 202246-25.8%Form 6-K FY2022Q4 Earnings Release ↗
FY2021Dec 31, 202162-12.7%Form 6-K FY2021Q4 Earnings Release ↗
FY2020Dec 31, 202071–Form 6-K FY2020Q4 Earnings Release ↗

Breakdown

What makes up nexium (esomeprazole) — Europe product sales

Cite this data

StockData. (2026). AstraZeneca Nexium (esomeprazole) — Europe product sales ($M), annual FY2020–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-nexium-eu

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.